Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
By G. Meyer, Z. Marjanovic, J. Valcke, B. Lorcerie, Y. Gruel, P. Solal-Céligny, C. le Maignan, J. Extra, P. Cottu, D. Farge. Archives of Internal Medicine, 2002
781 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine
View Paper: https://www.semanticscholar.org/paper/44e266e56dc9d88b45a2d5e9bc54ec1748fd05cf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Carrier
- C. Ay
- M. Di Nisio
- L. Hicks
- W. Wiercioch
- R. Morgan
- A. Leavitt
- F. Macbeth
Citations in the corpus
- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. (2021, methodology): “From these reviews, we identified 8 eligible RCTs that fulfilled our inclusion criteria and measured outcomes relevant to this question.(314-319) In all studies, LMWH was administered over 3 to 6 months, and the outcomes were assessed during that time frame.”